REG - CRISM Therapeutics - Positive Preclinical Data for Docetaxel ChemoSeed

CRISM TherapeuticsAnnouncement

21/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU1987Ba&default-theme=true

RNS Number : 1987B  CRISM Therapeutics Corporation  21 April 2026

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

21 April 2026

 

 

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

 

Positive preclinical data for Docetaxel-ChemoSeed in prostate cancer model

 

CRISM Therapeutics (AIM: CRTX), a UK clinical-stage drug delivery company
focused on the localised and sustained delivery of chemotherapy drugs, today
is pleased to announce positive preclinical results for its
Docetaxel-ChemoSeed implantable drug delivery technology, demonstrating
significant anti-tumour activity, evidence of dose response, and a favourable
tolerability profile compared to standard systemic docetaxel in a prostate
cancer model.

 

Prostate cancer, the most prevalent cancer in men, is the second programme in
CRISM's pipeline of product opportunities using the implantable ChemoSeed drug
delivery platform. The Company's most advanced programme, Irinotecan-ChemoSeed
in glioblastoma, remains on track for the first patients to be dosed in an
open label Phase 2 clinical trial in H1 2026.

 

The study evaluated tumour growth and tolerability across multiple treatment
groups, including untreated control, placebo, systemic docetaxel (standard of
care), and varying dose levels of Docetaxel-ChemoSeed.  Docetaxel-ChemoSeed
demonstrated consistent anti-tumour activity, a clear dose-response
relationship, and a favourable tolerability profile. Tumour volumes were
reduced across multiple dose levels, with the most pronounced effect
demonstrating a 58% reduction in tumour volume when compared to standard of
care. A dose-dependent trend was evident for Docetaxel-ChemoSeed, supporting
controlled drug delivery. Importantly, no adverse tolerability effects or
early terminations were observed in any ChemoSeed-treated groups, with body
weight remaining stable, whereas standard of care was associated with reduced
tolerability and multiple terminations. These findings demonstrate that the
sustained, localised delivery of docetaxel using CRISM's proprietary ChemoSeed
drug delivery platform, substantially enhances the efficacy of docetaxel
improving therapeutic outcomes while minimising systemic effects in the
treatment of prostate cancer.

 

These results further validate the Company's strategy to develop a localised
chemotherapy approach designed to overcome the limitations of systemic
treatment.

 

Chris McConville, Chief Scientific Officer of CRISM Therapeutics, said: "The
data clearly demonstrates that delivering chemotherapy locally and
continuously, rather than intermittently and systemically, provides a
much-needed improvement in therapeutic efficacy and tolerability. The
combination of tumour control, dose response and favourable tolerability
observed in this study is encouraging and underpins our confidence in the
potential of this technology as a localised treatment option for prostate
cancer. These findings strongly support the continued development of
Docetaxel-ChemoSeed and represent a meaningful step toward clinical
evaluation. We welcome discussions with potential partners and collaborators
as we build momentum towards first-in-human clinical trials."

- Ends -

 

Enquiries:

 

 Company                          Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation   S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, Executive Chairman  Richard Morrison                  Henry Harrison Topham

 Chris McConville, CSO            Vadim Alexandre                   Jamie Hooper

                                  Adam Cowl                         CRISM@buchanancomms.co.uk (mailto:CRISM@buchanancomms.co.uk)
 via Burson Buchanan              +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

The Company's LEI is 213800XFW6MKVCHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFZGZDVGNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved